Yamane K, Osawa M, Kobayashi I, Maruyama S
Jpn J Psychiatry Neurol. 1986 Jun;40(2):179-87. doi: 10.1111/j.1440-1819.1986.tb03140.x.
Despite the efforts of many workers, the cause and therapy has not been clarified. We carried out the therapeutic trial of thyrotropin releasing hormone (TRH) for amyotrophic lateral sclerosis (ALS) from January, 1979 to January, 1983. There were 16 subjects. The patients were given a low dose (0.5-2 mg) of TRH intravenously or intramusculary. Mild to moderate improvement was found in 9 (56%) of 16 patients. TRH has been reported to have the activating effects on the pyramidal tract, brainstem motor nuclei, and motoneuron in the spinal cord as a neurotransmitter or neuromodulator. We thought such action of TRH to be useful to the therapy of ALS.
尽管许多研究人员付出了努力，但肌萎缩侧索硬化症（ALS）的病因和治疗方法仍未明确。1979年1月至1983年1月，我们对促甲状腺激素释放激素（TRH）治疗肌萎缩侧索硬化症进行了临床试验。共有16名受试者。患者接受了低剂量（0.5 - 2毫克）的TRH静脉注射或肌肉注射。16名患者中有9名（56%）出现了轻度至中度的改善。据报道，TRH作为一种神经递质或神经调节剂，对锥体束、脑干运动核和脊髓运动神经元具有激活作用。我们认为TRH的这种作用对ALS的治疗是有益的。
